Emcure Pharmaceuticals Ltd (NSE:EMCURE) — Market Cap & Net Worth
Market Cap & Net Worth: Emcure Pharmaceuticals Ltd (EMCURE)
Emcure Pharmaceuticals Ltd (NSE:EMCURE) has a market capitalization of $4.09 Billion (Rs377.85 Billion) as of September 16, 2026. Listed on the NSE stock exchange, this India-based company holds position #4054 globally and #177 in its home market, demonstrating a 3.39% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Emcure Pharmaceuticals Ltd's stock price Rs1993.00 by its total outstanding shares 189589547 (189.59 Million). Also see Emcure Pharmaceuticals Ltd asset portfolio for a full breakdown of the balance sheet.
Emcure Pharmaceuticals Ltd Market Cap History: 2024 to 2026
Emcure Pharmaceuticals Ltd's market capitalization history from 2024 to 2026. Data shows growth from $2.97 Billion to $4.09 Billion (36.53% CAGR). Also see EMCURE cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Emcure Pharmaceuticals Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY 500
NIFTY500
|
$3.03 Trillion | 0.13% | #163 of 500 |
|
NIFTY SMALLCAP 250
NISM250
|
$402.60 Billion | 1.01% | #16 of 250 |
Weight: Emcure Pharmaceuticals Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Emcure Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Emcure Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check EMCURE live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.04x
Emcure Pharmaceuticals Ltd's market cap is 0.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.44x
Emcure Pharmaceuticals Ltd's market cap is 0.44 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $2.97 Billion | $65.82 Billion | $4.98 Billion | 0.05x | 0.60x |
| 2025 | $2.80 Billion | $78.08 Billion | $6.81 Billion | 0.04x | 0.41x |
| 2026 | $4.09 Billion | $92.04 Billion | $9.24 Billion | 0.04x | 0.44x |
Competitor Companies of EMCURE by Market Capitalization
Companies near Emcure Pharmaceuticals Ltd in the global market cap rankings as of September 16, 2026. Review EMCURE tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Emcure Pharmaceuticals Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Emcure Pharmaceuticals Ltd Historical Marketcap From 2024 to 2026
Between 2024 and today, Emcure Pharmaceuticals Ltd's market cap moved from $2.97 Billion to $ 4.09 Billion, with a yearly change of 36.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs4.09 Billion | +46.06% |
| 2025 | Rs2.80 Billion | -5.71% |
| 2024 | Rs2.97 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Emcure Pharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.09 Billion USD |
| MoneyControl | $4.09 Billion USD |
| MarketWatch | $4.09 Billion USD |
| marketcap.company | $4.09 Billion USD |
| Reuters | $4.09 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure X… Read more